Abeona Therapeutics (ABEO) Cantor Global Healthcare Conference 2025 summary

Commercial launch and product overview

• Achieved commercial-stage status with ZEVASKYN approval for recessive dystrophic EB (rDEB) in Q2, offering autologous cell-based gene therapy for large, chronic wounds.

• Early launch momentum includes 50 identified patients and two qualified treatment centers, with strong payer willingness and favorable coverage policies.

• ZEVASKYN is indicated for all rDEB patients, both adults and pediatrics, with an estimated 750 eligible patients across 23 centers of excellence.

• Clinical evidence demonstrates durable wound closure, with some patients showing healed wounds up to 10 years post-treatment.

• Demand is driven by both physician recommendation based on clinical data and patient advocacy, with many patients seeking repeat treatments.

Patient experience and logistics

• Patients typically have severe, non-healing wounds, many previously treated with other therapies or treatment-naïve.

• The treatment process involves initial consult, insurance clearance, financial arrangements, biopsy, and a 25-day manufacturing period, taking about 3-4 months initially.

• Patients are willing to travel significant distances for treatment, and as more centers open, access will improve.

• Repeat treatments are anticipated, with no payer-imposed cap on number of treatments or body surface area covered.

• Patient-to-patient advocacy and testimonials are increasing awareness and motivation for therapy uptake.

Market access, reimbursement, and capacity

• Strong balance sheet with $226 million, providing over two years of runway for launch execution.

• Payer response has been highly positive, with rapid prior authorization approvals and broad coverage, including UnitedHealthcare and Medicaid.

• No restrictions on concurrent or repeat use with other therapies, and no cap on number of treatments or sheets per patient.

• Manufacturing capacity is scaling from two to ten patients per month by mid-2026, with plans for further expansion and potential ex-U.S. supply.

• Breakeven is expected at more than three patients treated per month, with confidence in surpassing this in early 2026 as more centers come online.